

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5585298

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CENTRE FOR DRUG RESEARCH AND DEVELOPMENT	12/07/2018
RECEIVING PARTY DATA	
Name:	ZYMEWORKS INC.
Street Address:	540-1385 WEST 8TH AVENUE
City:	VANCOUVER
State/Country:	CANADA
Postal Code:	V6H 3V9
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15108258
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	ip-squire@squirepb.com
Correspondent Name:	TODD A. LORENZ
Address Line 1:	275 BATTERY STREET, SUITE 2600
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94111
ATTORNEY DOCKET NUMBER:	KRS-003/PCT/US
NAME OF SUBMITTER:	TODD A. LORENZ
SIGNATURE:	/Todd A. Lorenz, Reg. No. 39,754/
DATE SIGNED:	06/21/2019
Total Attachments: 5	
source=Assignment-KRS-003-PCT-NatApps-CDRD-to-Zymeworks#page1.tif	
source=Assignment-KRS-003-PCT-NatApps-CDRD-to-Zymeworks#page2.tif	
source=Assignment-KRS-003-PCT-NatApps-CDRD-to-Zymeworks#page3.tif	
source=Assignment-KRS-003-PCT-NatApps-CDRD-to-Zymeworks#page4.tif	
source=Assignment-KRS-003-PCT-NatApps-CDRD-to-Zymeworks#page5.tif	

ASSIGNMENT - WORLDWIDE

WHEREAS, CENTRE FOR DRUG RESEARCH AND DEVELOPMENT, (hereinafter referred to as "ASSIGNOR") having a place of business at 2405 Wesbrook Mall, Fourth Floor, Vancouver, British Columbia, V6T 1Z3, CANADA, co-owns the entire right, title and interest for, to and within all countries worldwide in and to an invention entitled: VAR2CSA-DRUG CONJUGATES (the "Invention"), described in the patent applications set forth in Appendix A attached hereto, and co-owns the entire right, title and interest for, to and within all countries in and to (a) any and all patent applications for the Invention in all countries and jurisdictions and under all conventions and treaties, including the right to claim for any and all applications any priority rights to which such applications are entitled under conventions, treaties or otherwise, and all divisions, extensions, continuations, continuations-in-part, provisionals, non-provisionals, substitutions and renewals thereof; (b) all Letters Patent which may be granted therefor in any and all countries and jurisdictions, and any renewals, reissues, re-examinations or extensions of the Letters Patent, and (c) the exclusive right to bring or participate in any proceeding for past infringement or any other actionable right under all of the foregoing and to receive all remedies that arise therefrom, to the end of the term for which the Letters Patent may be granted (the "Patent Rights").

WHEREAS, ZYMEWORKS INC. ("ASSIGNEE") having a place of business at 540-1385 West 8th Avenue, Vancouver, British Columbia, V6H 3V9, CANADA, is desirous of acquiring and having assigned to it ASSIGNOR's full right, title and interest in and to the Invention and the Patent Rights; and

WHEREAS the ASSIGNOR has agreed to make such assignment;

NOW, THEREFORE, in consideration of the foregoing premises, and of the sum of one dollar (\$1.00) and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the ASSIGNOR hereby sells, assigns and transfers absolutely to the ASSIGNEE the ASSIGNOR's full and exclusive right, title and interest in and to the Invention and the Patent Rights for, to and within all countries worldwide.

The ASSIGNOR hereby authorizes and requests the patent offices in all countries and jurisdictions to issue any and all of the Letters Patent, when granted, to the ASSIGNEE.


Further, the ASSIGNOR agrees that the ASSIGNOR will communicate to the ASSIGNEE or its representatives any facts known to ASSIGNOR respecting the Invention, and testify in any legal proceeding, sign all lawful papers, execute all papers relating to all patent

applications including all divisionals, continuations, continuations-in-part, extensions, renewals, provisionals, non-provisionals or substitutes thereof, and the Letters Patent including any renewal, re-examination, extension and reissue thereof, execute all necessary assignment papers to cause any and all of the Letters Patent to be issued to the ASSIGNEE, make all rightful oaths, and, generally do everything possible to aid the ASSIGNEE, its successors and assigns, to obtain and enforce proper protection for the Invention in any and all countries and jurisdictions.

The undersigned hereby authorizes the firm of Arnold & Porter Kaye Scholer LLP to correct errors in this assignment or to insert any further identification or other information necessary or desirable to make this Assignment suitable for recordal in any country.

This assignment may be executed in counterpart.

EXECUTION BY THE ASSIGNOR – CENTRE FOR DRUG RESEARCH AND DEVELOPMENT

By: 
(signature)

Name: Gordon C McEnty


Title: President & CEO

Date: December 7, 2018

At: VANCOUVER CANADA

(City & Country where Assignment Executed)

WITNESS:

By: 
(signature)

Name: Alexandra D'Andrea

ACKNOWLEDGMENT OF ASSIGNMENT

Acknowledgement of Receipt of Assignment by ZYMEWORKS INC.

WITNESS:

By: Jennifer Shaw
(signature)

By: A. D'Andrea
(signature)

Name: Jennifer Kaufman-Shaw

Name: Alexandria D'Andrea

Title: VP Intellectual Property

Date: December 7, 2018

At: Vancouver, BC, Canada
(City & Country where Assignment Executed)

APPENDIX A

Application Number	Filing Date	Title	Jurisdiction
2014373640	December 29, 2014	VAR2CSA- DRUG CONJUGATES	Australia
1120160151054	December 29, 2014	VAR2CSA- DRUG CONJUGATES	Brazil
2935064	December 29, 2014	VAR2CSA- DRUG CONJUGATES	Canada
201480076448.X	December 29, 2014	VAR2CSA- DRUG CONJUGATES	China
14874710.8	December 29, 2014	VAR2CSA- DRUG CONJUGATES	Europe
17104338.4	December 29, 2014	VAR2CSA- DRUG CONJUGATES	Hong Kong
201617022239	December 29, 2014	VAR2CSA- DRUG CONJUGATES	India
2016561041	December 29, 2014	VAR2CSA- DRUG CONJUGATES	Japan
20167020681	December 29, 2014	VAR2CSA- DRUG CONJUGATES	South Korea
MX/a/2016/008448	December 29, 2014	VAR2CSA- DRUG CONJUGATES	Mexico
2016130348	December 29, 2014	VAR2CSA- DRUG CONJUGATES	Russia
11201605260V	December 29, 2014	VAR2CSA- DRUG CONJUGATES	Singapore
15/108,258	December 29, 2014	VAR2CSA- DRUG CONJUGATES	United States
PCT/CA2014/000919	December 29, 2014	VAR2CSA- DRUG CONJUGATES	WIPO